scholarly journals Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry

2017 ◽  
Vol 117 (6) ◽  
pp. 775-782 ◽  
Author(s):  
Paula Jiménez Fonseca ◽  
◽  
Alberto Carmona-Bayonas ◽  
Raquel Hernández ◽  
Ana Custodio ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Registry ◽  
Real World ◽  
Real World Data ◽  
World Data ◽  
National Cancer Registry ◽  
Response To Chemotherapy

scholarly journals Treatment of advanced gastric cancer based on Lauren’s histological: Real-world data from the AGAMEMON National Cancer Registry

2017 ◽  
Vol 28 ◽  
pp. v231
Author(s):  
A. Carmona-Bayonas ◽  
P. Jiménez-Fonseca ◽  
R. Hernández ◽  
A. Custodio ◽  
J.M. Cano ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Cancer Registry ◽  
Real World ◽  
Real World Data ◽  
World Data ◽  
National Cancer Registry

scholarly journals Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States

2020 ◽  
Vol Volume 11 ◽  
pp. 27-43
Author(s):  
Lisa M Hess ◽  
Michael Grabner ◽  
Liya Wang ◽  
Astra M Liepa ◽  
Xiaohong Ivy Li ◽  
...  
Keyword(s):  
United States ◽  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Real World ◽  
The United States ◽  
Real World Data ◽  
World Data ◽  
Approved Drugs

scholarly journals O1-4 Survival time of nivolumab treatment in advanced gastric cancer from real-world data of the DELIVER trial (JACCRO GC-08)

2021 ◽  
Vol 32 ◽  
pp. S285
Author(s):  
Atsushi Ishiguro ◽  
Eisuke Inoue ◽  
Yasuhiro Sakamoto ◽  
Ryohei Kawabata ◽  
Yusuke Akamaru ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Survival Time ◽  
Advanced Gastric Cancer ◽  
Real World ◽  
Real World Data ◽  
World Data

Survival analysis by tumor response from real-world data in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 4044-4044
Author(s):  
Yosuke Kito ◽  
Eisuke Inoue ◽  
Yusuke Akamaru ◽  
Masazumi Takahashi ◽  
Jin Matsuyama ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Survival Time ◽  
Advanced Gastric Cancer ◽  
Real World ◽  
Tumor Response ◽  
Phase Iii ◽  
Clinical Factors ◽  
Real World Data ◽  
World Data

4044 Background: The phase III ATTRACTION-2 trial demonstrated survival benefit of nivolumab (Nivo) as third- or later-line treatment in previously treated advanced gastric or gastroesophageal junction (GEJ) cancer, with response rate (RR) of 11% (Kang YK, et al. Lancet 2017). It has been shown that some tumors grow rapidly after Nivo treatment, but the proportion and survival are still uncertain. We therefore prospectively investigated clinical outcomes from real-world data of Nivo treatment in advanced gastric cancer (GC). Methods: The DELIVER trial was a prospective, multicenter, observational study which assessed patients (pts) with advanced gastric or GEJ adenocarcinoma treated with Nivo alone and ECOG PS 0-2 (UMIN000030850). The aims were to evaluate the efficacy and safety of Nivo treatment in real world. Primary endpoint was overall survival (OS), secondary endpoints were RR, disease control rate (DCR), progression-free survival (PFS), tumor growth rate (TGR) at 1st evaluation, and safety. The sub-group analyses were performed for survival according to tumor response and clinical factors. The survival data was fixed at the timepoint of 1 year after the last enrollment. Results: In 501 pts enrolled from Mar 2018 to Aug 2019, 487 pts were evaluable (median age 70y, 71% male, ECOG PS0/1/2 42/44/14%, no. of prior regimen 1/2/≥3 2/39/59%, 21% HER2-pos, 42% pts with ascites). Median OS was 5.8 months (m) (95%CI 5.3-7.0) with 1y-survival rate of 30%, and median PFS was 1.8 m (95%CI 1.7-2.0), at 454 events for PFS and 389 events for OS. The DCR were 39.4%, and RR was 14.2% in 282 pts with measurable lesions. Median OS and PFS by tumor response (CR/PR/SD/PD) were Not Reached (NR)/NR/11.3/4.1m and NR/11.7/3.8/1.4m, respectively. A sub-group analysis of OS by clinical factors is the following: male/female; 6.5/5.0m ( p= 0.002), tub/por/sig; 8.1/5.4/4.1m ( p< 0.0001), albumin < 3.5/≥3.5; 4.2/8.9m ( p< 0.0001), w/peritoneal mets/w/o; 4.9/8.4m ( p< 0.0001), and w/ascites/w/o; 3.7/8.9m ( p< 0.0001). These findings were also observed in PFS. In 219 evaluable pts for TGR, 20.5% pts were identified as hyper-progressive disease (HPD). An exploratory approach by logistic regression analysis indicated that level of free-T3 in blood before Nivo treatment was higher in the HPD compared to the non-HPD group (2.5 vs. 2.2 pg/ml, p= 0.005). Survival time was comparable between the HPD group and PD without HPD group. Median period from 1st evaluation to death was 2.8 m for HPD, 5.7 m for non-HPD, and 2.4 m for PD at 1st evaluation without HPD. Conclusions: The real-world data of Nivo treatment in advanced GC indicated comparable survival to previous result in a clinical trial. Differences in survival time by tumor response or some clinical factors were observed in Nivo treatment. In addition, our study revealed the rate of HPD and the prognosis in advanced GC pts treated with Nivo. Clinical trial information: UMIN000030850.

scholarly journals 1423P Genomic landscape in advanced gastric cancer from real-world data (RWD) of clinical genomic testing

2021 ◽  
Vol 32 ◽  
pp. S1066-S1067
Author(s):  
H. Yamamoto ◽  
R. Oikawa ◽  
H. Takeda ◽  
K. Umemoto ◽  
A. Doi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Real World ◽  
Genomic Testing ◽  
Real World Data ◽  
World Data ◽  
Genomic Landscape ◽  
Clinical Genomic

scholarly journals Prognostic effect of surgery of metastases in patients with advanced gastric cancer: Real-world data from the AGAMENON registry

2017 ◽  
Vol 28 ◽  
pp. v236
Author(s):  
P. Jiménez-Fonseca ◽  
R. Hernandez ◽  
A. Custodio ◽  
A. Ramchandani Vaswani ◽  
M. Sánchez Cánovas ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Real World ◽  
Real World Data ◽  
World Data ◽  
Prognostic Effect

scholarly journals Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis

2018 ◽  
Vol 9 (3) ◽  
pp. 254-264 ◽  
Author(s):  
Laura Visa ◽  
Paula Jiménez-Fonseca ◽  
Elena Asensio Martínez ◽  
Raquel Hernández ◽  
Ana Custodio ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Real World ◽  
Older Patients ◽  
Efficacy And Safety ◽  
Real World Data ◽  
World Data
Sign in / Sign up

Export Citation Format

Share Document